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Introduction 
Our work was focused on the investigation for a ready 
to use prepared freeze dried rituximab immunoconjugates as 
potential radiopharmaceuticals for labeling with Lu-177 and 
Y-90 in order to increase the stability and higher efficiency 
and lower toxicity. We tested three bifunctional chelating 
agents (BFCA’s), p-SCN-Bn-DOTA, p-SCN-Bn-DTPA 
and 1B4M-DTPA conjugated to the same antibody using 
previously established protocol for conjugation (Gjorgieva 
Ackova, 2014, 2015; Smilkov, 2014).
The main goal was to investigate chemical character-
ization of the immunoconjugates, labeled with “cold” non-
radioactive isotopes of Lutetium and Yttrium in the same 
conditions as with radioactive Lutetium 177 and to show the 
chemical behavior and toxicological properties.
Material and method
The conjugation of antibody with three different bifunc-
tional cleating agents was performed using using previous-
ly established protocol for conjugation. The concentrations 
were adjusted to 1 mg/mL and the solutions were then ly-
ophilized. 
The purified immunoconjugates were formulated in ab-
sence of any cryoprotectant at the concentration of 10 mg/
mL, and subsequently lyophilized according to selected pro-
tocols.
The process of freeze drying was completed using Lab-
conco Free Zone Stoppering Tray Dryer, (USA), using pro-
tocol described by Park in 2013, modified to our experience.
Concentration of the antibody/immunoconjugate was 
determinate before and after freeze drying and reconstitu-
tion using UV spectrophotometer (Jenway UV/VIS spectro-
photometer 6715), and semi-micro UV polypropylene tubes 
with 0.1M PBS pH=8.0, at 280 nm in triplicate. 
After freeze drying both characterization of the conju-
gates and determination of the average number of BFCA at-
tached to each antibody molecule is performed by MALDI-
TOF mass spectrometry and integrity of the antibody was 
evaluated using SDS-PAGE electrophoresis, on 12% bis-tris 
acrylamide gel. 
The spectroscopic characterization of all three freeze 
dried immunoconjugates, in terms of monitoring the sec-
ondary protein structure (and its preservation), was achieved 
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by FT-IR and Raman spectroscopy.
The freeze dying immunoconjugates after reconsti-
tution were labeling with Lu-177 (555 MBq/mg in 0,5 M 
NH4OAc) and radiochemical purity was determined by in-
stant thin-layer chromatography on silica plates with a mo-
bile phase of ammonium acetate : methanol (1 : 1) using Cy-
clone Plus Phosphore Imager (Perkin Elmer). 
The obtained radioimmunoconjugates were characterized 
by SE-HPLC, using a Zorbax Bio Series GF-250 column and 
the elution process was monitored on UV detector at 280 nm 
and radiodetector (Wojdowska, 2014).
Toxicological studies were performed in Wistar rats af-
ter injection of rituximab labeled with cold Lutetium and 
Yttrium. Biodistribution studies were performed in 5-6 
week old nude mice grafted with Raji cells (2x106 cells in 
0.5 mL medium solution) after injection of radioactive Lu-
177-Rituximab.
Results and discussion
The 3 day protocol of freeze drying without the 
presence of mannitol, showed the greatest similarity in the 
elution profiles of the immunoconjugate prior lyophilization 
(Gholipour, 2014). 
After freeze drying, the pellets obtained corresponded to 
the composition and the time until complete reconstitution 
after addition of saline showed no significant difference in 
the time of complete dissolution of the lyophilisates, i.e. all 
tested samples were completely reconstituted in 2 min.
The average number of BFCA attached to each anti-
body molecule performed by MALDI-TOF mass spectrom-
etry shows presence of two main peaks corresponding to 
MW of 146491 Da (unconjugated antibody) and 149873 Da 
(conjugated antibody) which corresponds to an average of 
6.1 groups of p-SCN-Bn-DOTA (M = 551.61 g·mol-1), two 
peaks also, corresponding to MW of 146477 Da (unconju-
gated antibody) and 151246 Da (conjugated antibody) corre-
sponds to an average of 8.8 groups of p-SCN-Bn-DTPA (M 
= 540.54 g·mol-1) attached to a molecule of rituximab and 
two peaks corresponding to MW of 146848 Da (unconjugat-
ed antibody) and 151506 Da (conjugated antibody) corre-
sponding to average of 8.3 groups 1B4M-DTPA (M = 555.58 
g·mol-1) attached to a molecule of rituximab.
All immunoconjugates (both before and after lyophili-
zation) were separated in two distinct Mw species which mi-
grated in two bands (upper at ~50 kDa and lower at ~25 kDa) 
confirming the migration behavior typical for IgG antibod-
ies which are composed of twoidentical subunits each com-
posed by two polypeptide chains: two heavy and two light 
chains, linked via 4 disulfide bonds. The obtained fragments 
correspond to molecular masses of rituximab heavy and light 
chain given at the literature (Bil, 2007;)
In the experimental IR (in the region 2000-500 cm-
1) and Raman spectra (2000–400 cm-1 region) we observed 
retaining of native structure of the antibody and no obvious 
aggregation.
The radiochemical purity and determination of 
radioimmunoconjugates by SE-HPLC,  obtained after 
radiolabeling the with Lu-177 was higher than 5%. These 
conjugates were stable for 48h in 0.9% NaCl, however, 
progressive aggregation was observed.
Animal studies showed no toxicity and SPECT images 
in mice showed good localization of the tumor, as confirmed 
by ex-vivo organ counting. 
Conclusion
After evaluation of all the obtained results obtained we 
can conclude:
- Three immunoconjugates were synthesized, using 
p-SCN-Bn-DOTA, p-SCN-Bn-DTPA and 1B4M-
DTPA using the a selected ratio, 1:20
- Protocol for lyophilization was established, yielding 
lyophilisates with favorable physicochemical 
properties.
- The non-radioactive labeling with Y and Lu showed 
preserved secondary structure in all three types of 
immunoconjugate, confirming their stability in 
conditions of freeze-drying and labeling
- During labeling with Lu-177 all three types 
of radioimmunoconjugates showed high 
radiochemical purity, over 95%, which was 
confirmed both in ITLC and SE-HPLC.
The selection of the most appropriate immunoconjugate 
kit suitable for labeling with Lu-177 or with Y-90 can 
be made after stability study of the formulation and 
completition of cell culture studies.
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